Wall Street analysts forecast that Amyris, Inc. (NASDAQ:AMRS) will report earnings of ($0.13) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Amyris’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.15). Amyris posted earnings per share of ($0.50) during the same quarter last year, which indicates a positive year over year growth rate of 74%. The business is expected to issue its next quarterly earnings report before the market opens on Thursday, August 5th.
According to Zacks, analysts expect that Amyris will report full year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.39) to ($1.29). For the next financial year, analysts anticipate that the business will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.38) to ($0.15). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Amyris.
Amyris (NASDAQ:AMRS) last released its earnings results on Thursday, May 6th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.92). The company had revenue of $176.90 million for the quarter, compared to analysts’ expectations of $73.36 million. The business’s revenue for the quarter was up 507.9% compared to the same quarter last year.
Shares of AMRS stock traded up $0.39 during trading hours on Friday, reaching $15.93. 19,778 shares of the stock were exchanged, compared to its average volume of 2,989,757. The stock has a fifty day moving average price of $14.96. Amyris has a 12-month low of $1.88 and a 12-month high of $23.42. The stock has a market cap of $4.71 billion, a price-to-earnings ratio of -6.31 and a beta of 1.08.
In other news, CEO John Melo sold 95,115 shares of the firm’s stock in a transaction on Wednesday, July 7th. The stock was sold at an average price of $15.53, for a total value of $1,477,135.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 36.30% of the stock is currently owned by company insiders.
Several hedge funds have recently made changes to their positions in the company. Traynor Capital Management Inc. increased its position in shares of Amyris by 9.6% in the second quarter. Traynor Capital Management Inc. now owns 173,990 shares of the biotechnology company’s stock valued at $2,891,000 after buying an additional 15,300 shares in the last quarter. Golden Green Inc. purchased a new stake in Amyris during the 2nd quarter worth about $303,000. Principal Financial Group Inc. increased its position in Amyris by 14.8% during the 1st quarter. Principal Financial Group Inc. now owns 216,730 shares of the biotechnology company’s stock worth $4,140,000 after purchasing an additional 28,019 shares in the last quarter. Voloridge Investment Management LLC increased its position in Amyris by 215.9% during the 1st quarter. Voloridge Investment Management LLC now owns 779,471 shares of the biotechnology company’s stock worth $14,888,000 after purchasing an additional 532,734 shares in the last quarter. Finally, Amundi Asset Management US Inc. purchased a new stake in Amyris during the 1st quarter worth about $214,000. Institutional investors and hedge funds own 35.57% of the company’s stock.
Amyris, Inc engages in the provision of bioscience solutions. It offers its products to health and wellness, clean beauty, and flavor and fragrance markets. The company was founded by Jack D. Newman, Kinkead Keith Reiling, and Neil Renninger on July 17, 2003 and is headquartered in Emeryville, CA.
See Also: Blue-Chip Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.